Capital International Sarl Grows Stock Holdings in Icon Plc $ICLR

Capital International Sarl increased its stake in shares of Icon Plc (NASDAQ:ICLR) by 503.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 51,219 shares of the medical research company’s stock after purchasing an additional 42,727 shares during the period. Capital International Sarl’s holdings in Icon were worth $9,333,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Toth Financial Advisory Corp purchased a new position in shares of Icon during the fourth quarter valued at approximately $27,000. Ameriflex Group Inc. purchased a new position in shares of Icon during the third quarter valued at approximately $33,000. Johnson Financial Group Inc. purchased a new position in shares of Icon during the third quarter valued at approximately $71,000. Quadrant Capital Group LLC purchased a new position in shares of Icon during the third quarter valued at approximately $78,000. Finally, Geneos Wealth Management Inc. raised its holdings in shares of Icon by 11.5% during the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after purchasing an additional 56 shares during the last quarter. 95.61% of the stock is owned by hedge funds and other institutional investors.

Icon Stock Performance

Shares of ICLR opened at $149.45 on Monday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.10 and a quick ratio of 1.10. Icon Plc has a 1 year low of $66.57 and a 1 year high of $211.00. The company has a 50 day simple moving average of $117.51 and a two-hundred day simple moving average of $140.74. The firm has a market cap of $11.44 billion, a P/E ratio of 24.26, a price-to-earnings-growth ratio of 11.81 and a beta of 1.26.

Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, May 27th. The medical research company reported $2.21 earnings per share (EPS) for the quarter. Icon had a net margin of 5.98% and a return on equity of 9.50%. The business had revenue of $2.11 billion during the quarter. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. On average, equities analysts expect that Icon Plc will post 9.74 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ICLR. Weiss Ratings cut shares of Icon from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, May 29th. TD Cowen increased their price objective on shares of Icon from $120.00 to $164.00 and gave the stock a “buy” rating in a research note on Monday, June 1st. Citigroup increased their price objective on shares of Icon from $120.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, May 29th. Robert W. Baird set a $119.00 price objective on shares of Icon in a research note on Friday, February 13th. Finally, DA Davidson set a $164.00 price objective on shares of Icon in a research note on Monday, June 1st. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $156.44.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.